Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase

Biochemical Pharmacology

Volumn 57, Issue 4, 1999, Pages 397-406

  Bergman, Andries M ^a,e   Pinedo, Herbert M ^a,e   Jongsma, Ans P M ^a,b,e   Brouwer, Marjoleine ^b,e   Ruiz Van Haperen, Veronique W T ^c,e   Veerman, Gijsbert ^a,e   Leyva, Albert ^d,e   Eriksson, Steffan ^d,e   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

^e SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

ara C; Cytogenetic alterations; Deoxycytidine kinase activity; Drug accumulation; Drug resistance; Gemcitabine; Thymidine kinase activity

Indexed keywords

CYTARABINE; DEOXYCYTIDINE KINASE; GEMCITABINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME SPECIFICITY; FLOW CYTOMETRY; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; CYTARABINE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA; DRUG RESISTANCE; LEUKEMIA L1210; MICE; NUCLEOSIDE DEAMINASES; POLYPHOSPHATES; RATS; RATS, INBRED BN; SUBSTRATE SPECIFICITY; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0032898341     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00318-9     Document Type: Article

References (45)

1. Hertel L.W., Boder G.B., Kroin J.S., Rinzel S.M., Poore G.A., Todd G.C., Grindey G.B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 50:1990;4417-4422.
2. Braakhuis B.J., Ruiz van Haperen V.W.T., Boven E., Veerman G., Peters G.J. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol. 22:(Suppl 11):1995;42-46.
3. Kaye S.B. Gemcitabine Current Status of Phase I and II Trials . J. Clin. Oncol. 12:1994;1527-1531.
4. Abratt R.P., Rezwoda W., Falkson G., Goedhals L., Hacking D. Efficacy and safety profile of gemcitabine in non-small cell lung cancer Phase II study . J Clin Oncol. 12:1994;1535-1540.
5. Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 86:1994;1530-1533.
6. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
7. Ruiz van Haperen V.W.T., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol. 46:1993;762-766.
8. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
9. Eriksson S., Kierdaszuk B., Munch-Petersen B., Oberg B., Johansson N.G. Comparison of the substrate specifities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Comm. 176:1991;586-592.
10. Ross D.D., Chen S.R., Cuddy D.P. Effects of 1-β-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Cancer Res. 50:1990;2658-2666.
11. Schabel F.M. Jr, Skipper H.E., Trader M.W., Brockman R.W., Laster W.R. Jr, Corbbett T.H., Griswold D.P. Drug control of ara-C resistant tumor cells. Med Pediatr Oncol. 10:(Suppl 1):1982;125-148.
12. Skipper H.E., Schabel F.M. Jr, Lloyd H.N. Experimental therapeutics and kinetics Selection and overgrowth of specifically and permanently drug-resistant tumor cells . Semin Hematol. 15:1978;207-219.
13. Curt G.A., Clendininn N.J., Chabner B.A. Drug resistance in cancer. Cancer Treat Rev. 68:1984;87-99.
14. Wiley J.S., Jones S.P., Sawyer W.H. Cytosine arabinoside transport by human cells. Eur J Cancer Clin Oncol. 19:1983;1067-1074.
15. Capizzi R.L., Yang J.I., Rathmell J.P., White J.C., Cheng E., Cheng Y.C., Kufe T. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. Semin Oncol. 12:(Suppl 3):1985;65-74.
16. Chu M.Y., Fisher G.A. Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol. 14:1965;333-344.
17. Abe I., Saito S., Hosi K., Suzuki M., Sato H. Role of dephosphorylation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res. 42:1982;2846-2851.
18. Ruiz van Haperen V.W.T., Peters G.J. New targets for pyrimidine antimetabolites for the treatment of solid tumours 2: Deoxycytidine Kinase . Pharm World Sci. 16:1994;104-112.
19. Momparler R.L. Kinetic and template studies with cytosine arabinoside 5′-triphosphate and mammalian DNA polymerase. Mol Pharmacol. 8:1972;362-370.
20. Martens A.C., van Bekkum D.W., Hagenbeek A. The BN acute myelocytic leukemia (BNML), a rat model for studying human acute myelocytic leukemia (AML). Leukemia. 4:1990;241-257.
21. Hagenbeek A., Martens A.C., Colly L.P. In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia. Semin Oncol. 14:(Suppl 1):1987;202-206.
22. Lacaze N., Gombaud-Saintonge G., Lanotte M. Conditions controlling long-term proliferation of BN rat promyelocytic leukemia in vitro primary growth stimulation by microenvironment and establishment of an autonomous BN "leukemic stem cell line" Leukemia Res. 7:1983;145-154.
23. Richel D.J., Colly L.P., Arkesteijn G.J.A., Arentsen-Honders M.W., Kersten M.G.D., Ter Riet P.M., Willemze R. Substrate-specific deoxycytidine kinase deficiency in ara-C resistant leukemic cells. Cancer Res. 50:1990;6515-6519.
24. Brouwer M., Smets L.A., Jongsma A.P.M. Isolation and characterization of subclones of L1210 murine leukemia with different sensitivities to various cytotoxic agents. Cancer Res. 43:1983;2884-2888.
25. Peters G.J., Schornagel J.H., Milano G.A. Clinical pharmacokinetics of anti-metabolites. Cancer Surv. 17:1993;123-156.
26. Dofuku R., Matsuzawa A. A possible endomitotic origin of trisomy of chromosome 13 karyological implications for murine mammary tumorogenesis . Anticancer Res. 3:1983;17-34.
27. Ruiz van Haperen V.W.T., Veerman G., Braakhuis B.J.M., Vermorken J.B., Boven E., Leyva A., Peters G.J. Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer. 29A:1993;2132-2137.
28. Bradford M. A rapid and sensitive method for the qualification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
29. Much-Petersen B, Cloos L., Tyrsted G., Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 266:1991;9032-9038.
30. Ruiz van Haperen V.W.T., Veerman G., Boven E., Noordhuis P., Vermorken J.B., Peters G.J. Schedule dependence of sensitivity of 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol. 48:1994;1327-1339.
31. Noordhuis P., Kazemier K.M., Kaspers G.-J.L., Peters G.J. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Leukemia Res. 20:1996;127-134.
32. Russo S.A., Harris M.B., Greengard O. Lymphocyte thymidine kinase and treatment response in acute lymphocytic leukemia. Leukemia Res. 11:1987;149-154.
33. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem. 140:1994;1-22.
34. Peters G.J., Jansen G. Resistance to antimetabolites. Schilsky R.L., Milano G.A., Ratain M.J. Principles of Antineoplastic Drug Development and Pharmacology. 1996;543-585 Marcel Dekker, New York.
35. Shrecker A.W., Urshel M.J. Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210 studies with intact cells . Cancer Res. 28:1968;793-801.
36. Dollinger M.R., Burchenal J.H., Kreis W., Fox J.J. Analogues of 1-β-D-arabinofuranosylcytosine Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia. An in vitro deamination study . Biochem Pharmacol. 16:1967;689-706.
37. Kessel D., Hall T.C., Wodinsky I. Transport and phosphorylation as factors in the anti tumor action of cytosine arabinoside. Science. 156:1967;1240-1241.
38. Harris A.L., Grahame-Smith D.G., Potter C.G., Bunch C. Cytosine arabinoside deamination in human leukemic myeloblast and resistance to cytosine arabinoside therapy. Clin Sci. 60:1981;191-198.
39. Colly L.P., Peters W.G., Richel D., Arentsen-Honders M.W., Starrenburg C.W., Willemze R. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogeneous leukemia. Semin Oncol. 14:1987;257-261.
40. Plunkett W., Liliemark J.O., Adams T.M., Nowak B., Estey E., Kantarjian H., Keating M.J. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res. 47:1987;3005-3011.
41. Grunewald R., Kantarjian H., Keating M.J., Abbruzzese J., Tarassoff P., Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 50:1990;6823-6826.
42. Grunewald R., Abbruzzese J.L., Tarassoff P., Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 27:1991;258-262.
43. Heinemann V., Xu Y.-Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 38:1990;567-572.
44. Cory A.H., Hertel L.W., Kroin J.S., Cory J.G. Effects of 2′,2′-difluorodeoxycytidine (gemcitabine) on wild-type and variant mouse leukemia L1210 cells. Oncol Res. 5:1993;59-63.
45. Carella A.M., Berman E., Maraone M.P., Ganzina F. Idarubicin in the treatment of acute leukemias An overview of preclinical and clinical studies . Haematologica. 75:1990;159-169.